Form 4: Protagonist Therapeutics CEO Exercises Stock Options
SEC Form 4 Filing
Dinesh V. Patel, CEO of Protagonist Therapeutics, exercised stock options to acquire 24,000 shares of common stock on March 5, 2025.
Summary
- On March 5, 2025, Dinesh V. Patel, the President and CEO of Protagonist Therapeutics, exercised stock options.
- This transaction involved the acquisition of 24,000 shares of common stock at a price of $4.21 per share.
- Following the transaction, Patel directly owns 564,260 shares of common stock.
- Patel also holds 30,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity. The CEO exercising options can be seen as a positive signal, but it's not overwhelmingly so.
Positives
- The CEO's decision to exercise stock options could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from the CEO.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of the stock option exercise and transaction. |
| 04/29/2026 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.